Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likel...

Next Article

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Agilent agrees to acquire BIOVECTRA for $925m

Agilent agrees to acquire BIOVECTRA for $925m

Jul 24, 2024

‘Patients are not hot potatoes’: How the fight over dialysis coverage is putting kidney failure patients at risk

‘Patients are not hot potatoes’: How the fight over dia...

May 5, 2023

Advancing parenteral packaging production for the future of pharmaceuticals

Advancing parenteral packaging production for the futur...

May 2, 2023